CAMBRIDGE, Mass.–(BUSINESS WIRE)– Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical
company focused on the discovery, development and commercialization of
innovative therapeutics to treat serious and rare diseases, today
announced that senior management will participate in two upcoming
healthcare investor conferences in May.
|
Conference Details: |
|||
| Event: | Deutsche Bank 42nd Annual Health Care Conference | ||
| Date/Time: | May 4, 2017 at 8:40 a.m. EDT | ||
| Location: | Boston, MA | ||
| Event: | UBS Global Healthcare Conference | ||
| Date/Time: | May 22, 2017 at 10:30 a.m. EDT | ||
| Location: | New York, NY | ||
A live audio webcast for the Deutsche Bank and UBS Healthcare
Conferences will be available on the Investors/Media page of the
Company’s website at www.acceleronpharma.com.
A replay of the webcast will be available approximately two hours after
the event on the Acceleron website.
About Acceleron
Acceleron is a clinical stage biopharmaceutical company focused on the
discovery, development and commercialization of innovative therapeutics
to treat serious and rare diseases. Its pioneering research platform
leverages the powerful biology behind the body’s ability to rebuild and
repair its own cells and tissues. This approach to drug discovery has
generated four therapeutic candidates that are currently in clinical
trials. The Company’s lead therapeutic candidate, luspatercept, is being
evaluated in Phase 3 studies for the treatment of the hematologic
diseases myelodysplastic syndromes (MDS) and beta-thalassemia under a
global partnership with Celgene Corp. Acceleron is also advancing
clinical programs in the fields of oncology and neuromuscular diseases
and has a comprehensive preclinical research effort targeting fibrotic
and other serious diseases.
For more information, please visit www.acceleronpharma.com.
Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170501005095/en/
Contacts
Acceleron Pharma Inc.
Todd James, IRC, 617-649-9393
Senior
Director, Investor Relations and Corporate Communications
or
Media:
BMC
Communications
Brad Miles, 646-513-3125
Source: Acceleron Pharma Inc.
Cet article Acceleron to Participate in Two Healthcare Investor Conferences in May est apparu en premier sur EEI-BIOTECHFINANCES.